Matthew S. Davids. "BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia." Journal of Clinical Oncology, 2026. doi:10.1200/jco-25-02691